ASCO 2021: Pembrolizumab Shows Benefits in Adjuvant Setting for Clear-Cell Renal Cell Carcinoma
KEYNOTE-564 suggests pembrolizumab could become a standard of care in this setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.